Table 1.
Baseline clinical characteristics of the SURMOUNT-OSA participants (total randomized population).
| Characteristic | Study 1 |
Study 2 |
||||
|---|---|---|---|---|---|---|
| Tirzepatide MTD (n = 114) | Placebo (n = 120) | Total (n = 234) | Tirzepatide MTD (n = 120) | Placebo (n = 115) | Total (n = 235) | |
|
| ||||||
| BMI - kg/m2 | 39.7 ± 7.3 | 38.6 ± 6.7 | 39.1 ± 7.0 | 38.6 ± 6.1 | 38.7 ± 6.0 | 38.7 ± 6.0 |
| AHI - events/hr | 52.9 ± 30.5 | 50.1 ± 31.5 | 51.5 ± 31.0 | 46.1 ± 22.4 | 53.1 ± 30.2 | 49.5 ± 26.7 |
| OSA severity - n (%) | ||||||
| No Apnea | 0 (0.0 | 1 (0.8) | 1 (0.4) | – | – | – |
| Mild | 1 (0.9) | 2 (1.7) | 3 (1.3) | 0 (0.0) | 2 (1.8) | 2 (0.9) |
| Moderate | 39 (34.2) | 43 (36.1) | 82 (35.2) | 35 (29.4) | 37 (32.5) | 72 (30.9) |
| Severe | 74 (64.9) | 73 (61.3) | 147 (63.1) | 84 (70.6) | 75 (65.8) | 159 (68.2) |
| SASHB - %.min/hr (CV [%])a | 153.6 (102.7) | 137.8 (104.1) | 145.3 (103.4) | 132.2 (83.4) | 142.1 (112.5) | 137.0 (97.5) |
Data are for the total randomized population (as previously presented in Malhotra et al. (2024) [8].
Data are mean ± SD unless otherwise specified.
AHI = apnea-hypopnea index; BMI = body mass index; CV = coefficient of variation; OSA = obstructive sleep apnea; SASHB = sleep apnea-specific hypoxic burden; SD = standard deviation.
a
Data are geometric means (coefficient of variation, %).